Physician profile
Robert M Aronson
NPI 1598824039
$2,948.97
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,599 · 2020: $343 · 2021: $90.76 · 2022: $554 · 2023: $348 · 2024: $13.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $662.07 | 2019-2023 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.45 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $268.49 | 2019-2024 | |
| Grifols USA, LLC | $186.93 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $183.50 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $168.62 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $150.38 | 2019-2020 | |
| Philips North America LLC | $144.38 | 2019-2023 | |
| Mylan Specialty L.P. | $141.63 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $117.52 | 2019-2022 | |
| Electromed, INC. | $107.46 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $69.35 | 2022-2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $57.02 | 2023 | Glassia |
| Genzyme Corporation | $40.87 | 2019 | |
| Inogen, INC. | $36.08 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen One G3 Oxygen Concentrator |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $34.72 | 2019 | |
| Vapotherm INC | $30.86 | 2022 | |
| Merck Sharp & Dohme LLC | $27.72 | 2019-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $20.49 | 2023 | Lumryz |
| Axsome Therapeutics, INC. | $19.09 | 2022 | |
| Harmony Biosciences LLC | $17.99 | 2023 | Wakix |
| Shire North American Group INC | $16.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.14 | 2019 | |
| Insmed, INC. | $13.12 | 2019 | |
| Genentech USA, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Aronson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.